Aptevo Therapeutics Inc. Selling, General and Administrative Expense
Aptevo Therapeutics Inc. (APVO) reported Selling, General and Administrative Expense of $25.34 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2020-03-25
- Aptevo Therapeutics Inc. selling, general and administrative expense for the quarter ending 2019-12-31 was $4.99M, a 24.10% decline year-over-year.
- Aptevo Therapeutics Inc. selling, general and administrative expense for the quarter ending 2019-09-30 was $6.48M, a 6.69% decline year-over-year.
- Aptevo Therapeutics Inc. selling, general and administrative expense for the quarter ending 2019-06-30 was $6.54M, a 6.91% decline year-over-year.
- Aptevo Therapeutics Inc. selling, general and administrative expense for the quarter ending 2019-03-31 was $7.33M, a 3.45% decline year-over-year.
- Aptevo Therapeutics Inc. selling, general and administrative expense for fiscal 2019 was $25.34M, a 9.94% decline from fiscal 2018.
- Aptevo Therapeutics Inc. selling, general and administrative expense for fiscal 2018 was $28.13M, a 18.63% decline from fiscal 2017.
- Aptevo Therapeutics Inc. selling, general and administrative expense for fiscal 2017 was $34.58M, a 4.38% decline from fiscal 2016.
- Aptevo Therapeutics Inc. selling, general and administrative expense for fiscal 2016 was $36.16M, a 15.99% decline from fiscal 2015.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | $4.99M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $11.47M derived: sum of 2 quarters · filed 2020-03-25 | $18.01M derived: sum of 3 quarters · filed 2020-03-25 | $25.34M 10-K · filed 2020-03-25 | ||||
| 2019-09-30 | $6.48M 10-Q · filed 2019-11-07 | $13.01M derived: sum of 2 quarters · filed 2019-11-07 | $20.34M 10-Q · filed 2019-11-07 | $26.92M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2019-06-30 | $6.54M 10-Q · filed 2019-08-09 | $13.87M 10-Q · filed 2019-08-09 | $20.45M derived: sum of 3 quarters · filed 2020-03-25 | $27.39M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2019-03-31 | $7.33M 10-Q · filed 2019-05-09 | $13.91M derived: sum of 2 quarters · filed 2020-03-25 | $20.85M derived: sum of 3 quarters · filed 2020-03-25 | $27.87M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2018-12-31 | $6.58M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $13.52M derived: sum of 2 quarters · filed 2020-03-25 | $20.54M derived: sum of 3 quarters · filed 2020-03-25 | $28.13M 10-K · filed 2020-03-25 | ||||
| 2018-09-30 | $6.94M 10-Q · filed 2019-11-07 | $13.96M derived: sum of 2 quarters · filed 2019-11-07 | $21.56M 10-Q · filed 2019-11-07 | $30.11M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | $7.02M 10-Q · filed 2019-08-09 | $14.62M 10-Q · filed 2019-08-09 | $23.17M derived: sum of 3 quarters · filed 2019-08-09 | $30.64M derived: sum of 4 quarters · filed 2019-08-09 | ||||
| 2018-03-31 | $7.59M 10-Q · filed 2019-05-09 | $16.15M derived: sum of 2 quarters · filed 2019-05-09 | $23.62M derived: sum of 3 quarters · filed 2019-05-09 | $32.04M derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | $8.56M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $16.03M derived: sum of 2 quarters · filed 2019-03-18 | $24.45M derived: sum of 3 quarters · filed 2019-03-18 | $34.58M 10-K · filed 2019-03-18 | ||||
| 2017-09-30 | $7.47M 10-Q · filed 2018-11-14 | $15.89M derived: sum of 2 quarters · filed 2018-11-14 | $26.02M 10-Q · filed 2018-11-14 | $34.23M derived: sum of 4 quarters · filed 2018-11-14 | ||||
| 2017-06-30 | $8.42M 10-Q · filed 2018-08-09 | $8.76M 10-Q · filed 2017-08-10 | $18.55M 10-Q · filed 2018-08-09 | $19.30M 10-Q · filed 2017-08-10 | $26.75M derived: sum of 3 quarters · filed 2018-08-09 | $37.90M derived: sum of 4 quarters · filed 2018-08-09 | ||
| 2017-03-31 | $10.13M 10-Q · filed 2018-05-10 | $10.55M 10-Q · filed 2017-05-12 | $18.34M derived: sum of 2 quarters · filed 2018-05-10 | $29.48M derived: sum of 3 quarters · filed 2018-05-10 | $38.33M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2016-12-31 | $8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $19.35M derived: sum of 2 quarters · filed 2018-03-13 | $28.21M derived: sum of 3 quarters · filed 2018-03-13 | $36.16M 10-K · filed 2018-03-13 | $38.67M 10-K · filed 2017-03-31 | |||
| 2016-09-30 | $11.14M 10-Q · filed 2017-11-13 | $11.68M 10-Q · filed 2016-11-14 | $20.00M derived: sum of 2 quarters · filed 2017-11-13 | $27.95M 10-Q · filed 2017-11-13 | $29.96M 10-Q · filed 2016-11-14 | $43.56M derived: sum of 4 quarters · filed 2017-11-13 | ||
| 2016-06-30 | $8.86M 10-Q · filed 2017-08-10 | $18.28M 10-Q · filed 2017-08-10 | $32.42M derived: sum of 3 quarters · filed 2017-08-10 | $40.93M derived: sum of 4 quarters · filed 2017-08-10 | ||||
| 2016-03-31 | $9.42M 10-Q · filed 2017-05-12 | $23.56M derived: sum of 2 quarters · filed 2017-05-12 | $32.07M derived: sum of 3 quarters · filed 2017-05-12 | $42.53M derived: sum of 4 quarters · filed 2017-05-12 | ||||
| 2015-12-31 | $14.14M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $22.66M derived: sum of 2 quarters · filed 2017-03-31 | $33.11M derived: sum of 3 quarters · filed 2017-03-31 | $43.04M 10-K · filed 2017-03-31 | ||||
| 2015-09-30 | $8.51M 10-Q · filed 2016-11-14 | $18.97M derived: sum of 2 quarters · filed 2016-11-14 | $28.90M 10-Q · filed 2016-11-14 | |||||
| 2015-06-30 | $10.46M 10-Q/A · filed 2016-09-22 | $20.39M 10-Q/A · filed 2016-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |